GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » EPS (Diluted)

CARsgen Therapeutics Holdings (HKSE:02171) EPS (Diluted) : HK$-1.47 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings EPS (Diluted)?

CARsgen Therapeutics Holdings's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$-0.67. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.47.

CARsgen Therapeutics Holdings's EPS (Basic) for the six months ended in Dec. 2023 was HK$-0.67. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.47.

CARsgen Therapeutics Holdings's EPS without NRI for the six months ended in Dec. 2023 was HK$-0.67. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.47.

During the past 3 years, the average EPS without NRIGrowth Rate was -27.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, CARsgen Therapeutics Holdings's highest 3-Year average EPS without NRI Growth Rate was -27.30% per year. The lowest was -59.60% per year. And the median was -43.45% per year.


CARsgen Therapeutics Holdings EPS (Diluted) Historical Data

The historical data trend for CARsgen Therapeutics Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARsgen Therapeutics Holdings EPS (Diluted) Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
-0.52 -2.22 -15.01 -1.81 -1.47

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only -0.76 -0.81 -1.04 -0.80 -0.67

Competitive Comparison of CARsgen Therapeutics Holdings's EPS (Diluted)

For the Biotechnology subindustry, CARsgen Therapeutics Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CARsgen Therapeutics Holdings's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where CARsgen Therapeutics Holdings's PE Ratio falls into.



CARsgen Therapeutics Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

CARsgen Therapeutics Holdings's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-817.921-0)/558.055
=-1.47

CARsgen Therapeutics Holdings's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-375.518-0)/560.635
=-0.67

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CARsgen Therapeutics Holdings  (HKSE:02171) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


CARsgen Therapeutics Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of CARsgen Therapeutics Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


CARsgen Therapeutics Holdings (HKSE:02171) Business Description

Traded in Other Exchanges
Address
No. 388 Yindu Road, Building 12, CMC Preparation Center, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a global clinical-stage biopharmaceutical company discovering, researching and developing cell therapies in the People's Republic of China and the United States of America.
Executives
Guo Bingsen 2401 A concert party to an agreement to buy shares
Guo Huaqing 2101 Beneficial owner
Li Zonghai 2401 A concert party to an agreement to buy shares
Wang Huamao 2401 A concert party to an agreement to buy shares
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Private Limited 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Yang Zhi 2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd 2201 Interest of corporation controlled by you
Bvcf Realization Fund, L.p. 2201 Interest of corporation controlled by you
Bvcf Realization Fund Gp, Ltd. 2201 Interest of corporation controlled by you
Zhejiang Jolly Healthcare Investment Management Limited 2201 Interest of corporation controlled by you
Applied Biomaterial Ltd. 2201 Interest of corporation controlled by you
Zhejiang Jolly Pharmaceutical Co., Ltd. 2201 Interest of corporation controlled by you
Zhejiang Zuoli Innovation Medical Investment Management Co., Ltd. 2101 Beneficial owner

CARsgen Therapeutics Holdings (HKSE:02171) Headlines

No Headlines